Format

Send to

Choose Destination
Curr Opin Investig Drugs. 2004 Mar;5(3):276-82.

Urotensin-II as a novel therapeutic target in the clinical management of cardiorenal disease.

Author information

1
Department of Medicine, St Vincent's Hospital, University of Melbourne, Fitzroy, Victoria 3065, Australia.

Abstract

The pronounced pharmacodynamic effects of human urotensin-II (U-II), a 'somatostatin-like' cyclic undecapeptide, are mediated via the G protein-coupled receptor UT (formerly known as GPR14). Emerging clinical studies implicate U-II in the etiology of several cardiorenal and metabolic disease states in humans. Although the specific pathogenic role(s) of U-II remain to be clearly defined, existing data warrant further clinical investigation. The therapeutic development of specific U-II/UT inhibitors will assist in establishing a causative role for U-II in the progression and/or maintenance of hypertension, heart failure, renal tubular disease and diabetes.

PMID:
15083593
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center